ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

10,235Medicare Part D Prescriptions Filled, Including Refills

Rank: 75 out of 807

$591K Total Retail Price of All Prescriptions

Rank: 71 out of 807

638 Patients Receiving at Least One Drug in Part D
88%Patients 65 Years and Older
22% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Minnesota
Lower avg

Schedule Two
Controlled Substances

4% of this provider’s 638 patients filled at least one prescription for a schedule two drug, compared to an average of 5%.

Schedule Three
Controlled Substances

5% of this provider’s 638 patients filled at least one prescription for a schedule three drug, compared to an average of 6%.

Risky Drugs to Seniors

2% of this provider’s 9,048 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

21% of this provider’s prescriptions were for brand-name drugs, compared to an average of 22%.

Prescription Price

$58 was the average price of a prescription from this provider, compared to $58 among peers.

Prescriptions per Patient

16 is the average number of prescriptions (including refills) per patient, compared to an average of 16.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Minnesota
SIMVASTATIN 530 487 1 1
LEVOTHYROXINE SODIUM 437 396 2 3
OMEPRAZOLE 392 364 3 4
LOSARTAN POTASSIUM 301 295 4 14
FUROSEMIDE 276 269 5 6
AMLODIPINE BESYLATE 274 242 6 5
ATENOLOL 262 240 7 7
LOSARTAN-HYDROCHLOROTHIAZIDE 210 196 8 55
LISINOPRIL 199 184 9 2
ZOLPIDEM TARTRATE 178 170 10 23
CITALOPRAM HBR 163 128 11 17
ATORVASTATIN CALCIUM 162 147 12 11
DONEPEZIL HCL 146 146 13 31
AZITHROMYCIN 143 121 14 57
METOPROLOL SUCCINATE 140 124 15 13
WARFARIN SODIUM 135 116 16 10
TRAZODONE HCL 132 112 17 25
PREDNISONE 127 118 18 24
POTASSIUM CHLORIDE 125 122 19 18
TRAMADOL HCL 123 104 20 19
HYDROCODONE-ACETAMINOPHEN 114 82 S3 21 15
METOPROLOL TARTRATE 109 75 22 8
HYDROCHLOROTHIAZIDE 107 103 23 9
LISINOPRIL-HYDROCHLOROTHIAZIDE 106 94 24 28
ESCITALOPRAM OXALATE 106 100 24 115
GABAPENTIN 105 100 26 16
METFORMIN HCL 96 82 27 12
ALENDRONATE SODIUM 94 92 28 20
CELEBREX 91 87 29 87
CIPROFLOXACIN HCL 86 82 30 72
VENLAFAXINE HCL ER 84 79 31 91
METHYLPREDNISOLONE 78 73 32 136
METFORMIN HCL ER 74 56 33 61
FAMOTIDINE 71 45 34 90
ADVAIR DISKUS 68 44 35 33
MIRTAZAPINE 68 65 35 38
PRAVASTATIN SODIUM 67 67 37 21
FLUTICASONE PROPIONATE 66 57 38 30
PANTOPRAZOLE SODIUM 65 54 39 44
TRIAMTERENE-HCTZ 62 51 40 29
JANTOVEN 61 61 41 37
KLOR-CON 10 59 55 42 81
SERTRALINE HCL 57 56 43 22
ALLOPURINOL 57 54 43 26
ACTONEL 52 51 45 261
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Oct. 20, 2011.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.